4.54
4.54 (0%)
As of Apr 17, 2025
Mannkind Corp [MNKD]
Source:
Company Overview
Mannkind Corp is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
| Country | United States |
| Headquarters | danbury, connecticut |
| Phone Number | ( 818 ) 661-5000 |
| Industry | manufacturing |
| CEO | Michael E. Castagna |
| Website | www.mannkindcorp.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $285.5 |
| Operating Profit | $72.6 |
| Net Income | $27.6 |
| Net Cash | $-191.4 |
Profit Ratios
| Gross Margin | $268.1 |
| Operating Margin | 25.4 |
| Profit as % of Revenues | 971.7% |
| Profit as % of Assets | 6.4% |
| Profit as % of Stockholder Equity | -35% |
Management Effectiveness
| Return on Equity | -35% |
| Return on Assets | 7% |
| Turnover Ratio | 65.7% |
| EBITA | $72.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $393.8 |
| Total Liabilities | $472.7 |
| Operating Cash Flow | $42.5 |
| Investing Cash Flow | $-96.6 |
| Financing Cash Flow | $-137.3 |
